Overview

RS Oncology is a clinical stage biotech company bringing targeted medicine and novel treatments for rare and orphan diseases. Partnering with University of Vermont and the Cunniff Lab,  RSO is currently testing therapies for patients suffering from Malignant Pleural Effusion and/or Malignant Pleural Mesothelioma. The Phase 1 clinical trial is currently in process throughout the United Kingdom with the expectation of completing Phase 1 and commencing Phase 2 later this year.

Company News

News

RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of Aggressive Mesotheliomas, Improving Druggability

Sep 13, 2023

Posted by RS Oncology LLC

News

RS Oncology Announces Completion of First-in-Human Phase 1 Clinical Trial of RSO-021, a Novel Irreversible Inhibitor of Mitochondrial PRX3

Sep 12, 2023

Posted by RS Oncology LLC

See all Members